



Full paper/Mémoire

# Spectroscopic, theoretical, and antibacterial approach in the characterization of 5-methyl-5-(3-pyridyl)-2,4-imidazolinedione ligand and of its platinum and palladium complexes

Seyyed Javad Sabounchei<sup>a,\*</sup>, Parisa Shahriary<sup>a</sup>, Sadegh Salehzadeh<sup>a</sup>,  
Yasin Gholiee<sup>a</sup>, Abdolkarim Chehregani<sup>b</sup>

<sup>a</sup> Faculty of Chemistry, Bu-Ali Sina University, 65174 Hamedan, Iran

<sup>b</sup> Faculty of Science, Department of Biology, Bu-Ali Sina University, 65174 Hamedan, Iran

## ARTICLE INFO

## Article history:

Received 1st March 2014

Accepted after revision 10 April 2014

Available online 23 March 2015

## Keywords:

2,4-imidazolinedione

Pt complex

Pd complex

Density functional theory

Antibacterial activity

## ABSTRACT

A series of Pt(IV), Pt(II), and Pd(II) complexes (PtCl<sub>4</sub>L<sub>2</sub> (**1**), PtCl<sub>2</sub>L<sub>2</sub> (**2**), PdCl<sub>2</sub>L<sub>2</sub> (**3**), and Pd<sub>2</sub>Cl<sub>4</sub>L<sub>2</sub> (**4**)) with 5-methyl-5-(3-pyridyl)-2,4-imidazolinedione ligand (**L**) have been synthesized by the reaction of metal chlorides (K<sub>2</sub>[PtCl<sub>6</sub>], K<sub>2</sub>[PtCl<sub>4</sub>], K<sub>2</sub>[PdCl<sub>4</sub>], and PdCl<sub>2</sub>) with **L** in 1:2 (**1–3**) and 1:1 (**4**) molar ratios. The binding manner of **L**, and the composition and geometry of the metal complexes were examined by elemental analysis, IR, <sup>1</sup>H, and <sup>13</sup>C NMR spectroscopies. Theoretical calculations invoking geometry optimization of different isomers, performed using density functional theory, suggested that in both gas and solution phases the *trans* isomers are more stable than the *cis* ones. The experimental results and calculated molecular parameters, bond distances and angles, revealed slightly distorted octahedral (**1**) and square-planar (**2–4**) geometry around the metallic center through the pyridine-type nitrogen (N<sub>py</sub>) and chlorine atoms. In **4**, the binuclear complex, each palladium atom is coordinated by one nitrogen and three chlorine atoms (one as terminal and two as bridging ligands). Antibacterial activity of **L** and the corresponding complexes was investigated against six species of microorganisms. Testing was performed by disk diffusion method and minimum inhibitory concentrations (MIC) have been determined. The results showed that the title compounds have the capacity of inhibiting the metabolic growth of bacteria to different extents. In general, the binuclear palladium(II) complex was the most active one.

© 2014 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.

## 1. Introduction

Several classes of antimicrobial compounds are presently available; microorganism's resistance to these drugs constantly emerges. In order to prevent this serious

medical problem, the elaboration of new types of antibacterial agents or the expansion of bioactivity of the naturally known biosensitive compounds is a very interesting research area. The synthesis and characterization of metal complexes with organic bioactive ligands is one of the promising fields for this search. The hydantoin scaffold is a useful structural motif for displaying chemical functionality in biologically active molecules [1]. Strong evidence is available, indicating the crucial effect of the

\* Corresponding author.

E-mail address: jsabounchei@yahoo.co.uk (S.J. Sabounchei).

nature of C-5 substituents on the pharmacological action [2]. The biological activities of the metal complexes differ from those of either the ligand or the metal ion. The results obtained thus far have led to the conclusion that structural factors that govern antimicrobial activities are strongly dependent on the central metal ion. Numerous complexes based on platinum(II) and platinum(IV) ion have been synthesized, and their antimicrobial activities have been documented [3–9]. Pt(II) complexes show several restrictions compared with those of Pt(IV) while the latter ones are also cytotoxic in nature and have some advantages in comparison to Pt(II) complexes [10–13]. In general, the use of Pd(II) and of its complexes in medicine is limited. The coordination chemistry of palladium(II) is very similar to that of platinum(II), but the higher lability in ligand exchange at the Pd center ( $10^5$ -fold vs. Pt) may cause rapid hydrolysis processes, leading to the dissociation of the complex and to the formation of very reactive species unable to reach their biological targets [14]. These problems could be overcome by using the bulky heterocyclic and chelating ligands. A number of palladium complexes with aromatic N-, N,N-, N,O-, and N,S-containing ligands have shown antibacterial characteristics [5–9,13–17].

Continuing our research program on the preparation of metal complexes with 5-methyl-5-pyridylhydantoin with potential biological activity [4,18–20], with a view to diversifying the coordination behavior of **L** and the biological importance of platinum and palladium complexes, it has been considered worthwhile to synthesize and characterize some new platinum(IV), platinum(II), and

palladium(II) derivatives of 5-methyl-5-(3-pyridyl)-hydantoin, **1–4**, Scheme 1, which could be proved to be antibacterial agents. All compounds have been studied by DFT calculations in order to correlate the theoretical results with the experimental ones.


## 2. Material and methods

### 2.1. Materials and physical measurements

All necessary chemicals obtained from commercial suppliers were reagent grade and used without further purification. Carbon, nitrogen, and hydrogen contents of the compounds were determined by elemental analysis carried out on a 'Vario EL III' elemental analyzer. IR spectra were recorded on PerkinElmer and Bruker vertex 70 FT-IR spectrophotometers in the ranges from 4000 to 400 and from 400 to  $150\text{ cm}^{-1}$  on KBr and ATR cells, respectively. NMR spectra were obtained on 90 MHz Jeol and 300 MHz Bruker spectrometers in DMSO- $d_6$  as the solvent. The melting points were determined using a SMP<sub>3</sub> apparatus.

### 2.2. Computational details

Geometries of **L** and the corresponding complexes in the gas phase were fully optimized using the BP86 functional [21,22]. The def2-TZVP [23] basis set was employed for all atoms, and structures were optimized without symmetry restrictions. All calculations were performed using the Gaussian 03 set of programs [24]. The conductor-like polarizable continuum model



Scheme 1. Synthesis routes of complexes 1–4.

(CPCM) [25] as implemented in Gaussian 03 was used for the prediction of the solvent's influence on the relative stability of complexes. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR shielding results were obtained at the same level of theory. The  $^1\text{H}$  and  $^{13}\text{C}$  isotropic shielding constants were calculated using the gauge-independent atomic orbital (GIAO) method [26,27].

### 2.3. Antibacterial study

#### 2.3.1. Test organisms

Standard strains of the following microorganisms were used as test organisms: *Staphylococcus aureus* (ATCC 6633), *Staphylococcus saprophyticus* (ATCC 15305), *Escherichia coli* (Lio), *Proteus vulgaris* (Lio), *Serratia marcescens* (PTCC 1330), and *Bacillus cereus* (ATCC 7064). Some microorganisms were obtained from Persian Type Culture Collection, Tehran, Iran and others were locally isolated (Lio). The organisms were sub-cultured in nutrient broth and nutrient agar (Oxoid Ltd.) for using in experiments while diagnostic sensitivity test agar (DST) (Oxoid Ltd.) was used in antibiotic sensitivity testing. The composition of nutrient agar culture medium is: 0.5% peptone, 0.3% beef extract or yeast extract, 1.5% agar, 0.5% NaCl, and distilled water; pH was adjusted to neutral (6.8) at 25 °C.

#### 2.3.2. Sensitivity testing

For bioassays, a suspension of approximately  $1.5 \times 10^8$  cells per  $\text{cm}^3$  in sterile normal saline was prepared as described by Forbes et al. [28]. Sensitivity testing was determined using the agar-well diffusion method [29]. In each disk, 30  $\mu\text{dm}^3$  of **L** and complexes **1–4** were loaded. The bacterial isolates were first grown in nutrient broth for 18 h before use. The inoculum suspensions were standardized and then tested against the effect of the chemicals at amounts of 30  $\mu\text{dm}^3$  for each disk in DST medium. The plates were later incubated at  $37 \pm 0.5$  °C for 24 h, after which they were observed for zones of inhibition, an area of media where bacteria are unable to grow due to the presence of a drug that impedes their growth. The effects were compared with that of the standard antibiotic chloramphenicol at a concentration of 1  $\text{mg}/\text{cm}^3$  [30]. The minimum inhibitory concentration (MIC) of chemicals was determined by tube dilution techniques in Mueller–Hinton broth (Merck) according to NCCLS [31]. The experiments were repeated at least three to five times for each organism and data are presented as the mean  $\pm$  SE of 3–5 samples.

## 3. Experimental

### 3.1. Synthesis and characterization

#### 3.1.1. Synthesis of $(\text{C}_9\text{H}_9\text{N}_3\text{O}_2)$ (**L**)

This ligand was prepared by a previously published method [32]. Since in the original work this compound was poorly characterized, and also for comparative purposes, spectroscopic characterization of **L** was performed [20].

#### 3.1.2. Synthesis of $\text{PtCl}_4(\text{C}_9\text{H}_9\text{N}_3\text{O}_2)_2$ (**1**)

$\text{K}_2[\text{PtCl}_6]$  (0.2429 g, 0.5 mmol) in 15  $\text{cm}^3$  water, dissolved on a steam bath within 50 min, was added to

a solution of **L** (0.1911 g, 1 mmol) in 6  $\text{cm}^3$  of a 50% water/ethanol mixture, and the resulting yellow solution was stirred at 600 rpm and 50 °C for 72 h under an  $\text{N}_2$  atmosphere. The solid product was precipitated from the reaction mixture by solvent evaporation. The stable complex was filtered off, washed with cold water, and dried under vacuum. The purity was checked up by thin layer chromatography with the eluent  $\text{CH}_3\text{COOC}_2\text{H}_5/\text{C}_2\text{H}_5\text{OH} = 2:1$ . The substance is soluble in DMSO. Yield: 0.3460 g (96.2%). M.P. = 235–237 °C. Anal. calcd. for  $\text{PtCl}_4\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_4$ : C, 30.06; H, 2.52; N, 11.68. Found: C, 29.70; H, 2.61; N, 11.33.

#### 3.1.3. Synthesis of $\text{PtCl}_2(\text{C}_9\text{H}_9\text{N}_3\text{O}_2)_2$ (**2**)

$\text{K}_2[\text{PtCl}_4]$  (0.2075 g, 0.5 mmol) in 3  $\text{cm}^3$  of water was added to a solution of **L** (0.1911 g, 1 mmol) in 6  $\text{cm}^3$  of a 50% water/ethanol mixture and the resulting solution was stirred at 600 rpm and 50 °C for 24 h under an  $\text{N}_2$  atmosphere. The solid product precipitated from the reaction mixture. The stable complex was filtered off, washed with cold water, and dried under vacuum. The purity was checked up by thin layer chromatography with the eluent  $\text{CH}_3\text{COOC}_2\text{H}_5/\text{C}_2\text{H}_5\text{OH} = 2:1$ . The substance is soluble in DMSO. Yield: 0.2800 g (86.4%). M.P. = 330–331 °C. Anal. calcd. for  $\text{PtCl}_2\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_4$ : C, 33.34; H, 2.80; N, 12.96. Found: C, 33.50; H, 2.48; N, 12.81.

#### 3.1.4. Synthesis of $\text{PdCl}_2(\text{C}_9\text{H}_9\text{N}_3\text{O}_2)_2$ (**3**)

$\text{K}_2[\text{PdCl}_4]$  (0.1632 g, 0.5 mmol) in 2  $\text{cm}^3$  of water was added to a stirred solution of **L** (0.1911 g, 1 mmol) at 600 rpm in 6  $\text{cm}^3$  of a 50% water/ethanol mixture for 3 h at room temperature. The solid product precipitated from the reaction mixture. The stable complex was filtered off, washed with cold water, and dried under vacuum. The purity was checked up by thin layer chromatography with the eluent  $\text{CH}_3\text{COOC}_2\text{H}_5/\text{C}_2\text{H}_5\text{OH} = 2:1$ . The substance is soluble in DMSO. Yield: 0.2115 g (75.6%). M.P. = 233–234 °C. Anal. calcd. for  $\text{PdCl}_2\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_4$ : C, 38.63; H, 3.24; N, 15.02. Found: C, 38.30; H, 3.39; N, 14.73.

**Table 1**

IR selected bands ( $\nu/\text{cm}^{-1}$ ) of the ligand [20] and complexes; for the numbering of atoms, see Fig. 1.

Compound	$\nu_{(\text{NH})}$	$\nu_{(\text{CO})}$	$\nu_{(\text{CN})}$	$\nu_{(\text{MCl})}$
<b>L</b>	3244 (N2–H3) 3170 (N3–H4)	1771 (C8–O2) 1723 (C6–O1)	1594	–
<b>1</b>	3212 3129	1777 1732	1610	344 (Pt–Cl)
<b>2</b>	broad 3129	1780 1728	1611	329 (Pt–Cl)
<b>3</b>	3257 3116	1778 1728	1606	360 (Pd–Cl)
<b>4</b>	3267 3119	1774 1725	1609	375 (Pd–Cl, terminal) 305 (Pd–Cl, bridging, trans to Cl) 249 (Pd–Cl, bridging, trans to L)

**Table 2**  
Experimental and theoretical  $^1\text{H}$  and  $^{13}\text{C}$ NMR chemical shifts/ppm for the ligand [20] and corresponding complexes; for the numbering of atoms, see Fig. 1.

Compound		$^1\text{HNMR}$						
		5,6,7-H	9-H	2-H	8-H	1-H	3-H	4-H
<b>L</b>	Exp.	1.69	7.39	7.88	8.51	8.71	8.71	–
	Theo.	1.64	7.31	8.24	8.87	9.01	4.38	5.89
<b>1</b>	Exp.	1.60	7.84	8.40	8.79	8.81	8.72	10.97
	Theo.	1.68	7.49	8.62	9.75	9.96	4.73	6.00
<b>2</b>	Exp.	1.61	7.51	8.06	8.81	8.84	8.65	10.96
	Theo.	1.64	7.29	8.35	9.33	9.53	4.70	5.94
<b>3</b>	Exp.	1.70	7.62	8.13	8.68	8.84	8.77	11.06
	Theo.	1.63	7.29	8.36	9.45	9.67	4.71	5.94
<b>4</b>	Exp.	1.70	7.59	8.13	8.79	8.79	8.73	11.04
	Theo.	1.65	7.24	8.40	8.37	9.72	4.71	5.99

Compound		$^{13}\text{CNMR}$								
		C-9	C-7	C-3	C-4	C-5	C-2	C-1	C-6	C-8
<b>L</b>	Exp.	25.45	63.24	123.89	133.78	136.06	147.14	149.35	157.29	177.52
	Theo.	30.53	72.82	125.26	136.36	140.00	154.14	149.20	153.66	176.36
<b>1</b>	Exp.	25.15	63.01	126.79	138.81	140.64	150.62	153.00	156.55	175.92
	Theo.	31.28	73.04	126.45	139.54	142.49	157.24	154.35	153.14	175.59
<b>2</b>	Exp.	25.65	62.68	126.68	136.81	138.91	150.26	152.71	156.37	175.93
	Theo.	31.07	73.09	125.72	136.66	140.83	155.38	152.06	153.30	175.80
<b>3</b>	Exp.	25.46	62.79	125.67	137.39	137.84	150.13	153.09	156.45	176.16
	Theo.	31.14	73.03	125.98	137.35	140.99	156.89	153.54	153.31	155.77
<b>4</b>	Exp.	25.50	62.82	125.68	137.40	137.85	150.13	153.05	156.43	176.18
	Theo.	30.85	72.79	126.84	137.93	143.59	155.29	154.13	153.14	157.70

### 3.1.5. Synthesis of $\text{Pd}_2\text{Cl}_4(\text{C}_9\text{H}_9\text{N}_3\text{O}_2)_2$ (**4**)

$\text{PdCl}_2$  (0.1772 g, 1 mmol) in  $20 \text{ cm}^3$  acetonitrile was refluxed for 24 h and then added to a stirred solution of **L** (0.1911 g, 1 mmol) at 600 rpm in  $5 \text{ cm}^3$  of a 50% water/acetonitrile mixture for 3 h at room temperature. The solid product precipitated from the reaction mixture. The stable complex was filtered off, washed with cold diethyl ether, and dried under vacuum. The purity was checked up by thin layer chromatography with the eluent  $\text{CH}_3\text{COOC}_2\text{H}_5/\text{C}_2\text{H}_5\text{OH} = 2:1$ . The substance is soluble in DMSO. Yield: 0.3009 g (81.7%). M.P. = 285–287 °C. Anal. calcd. for  $\text{Pd}_2\text{Cl}_4\text{C}_{18}\text{H}_{18}\text{N}_6\text{O}_4$ : C, 29.33; H, 2.46; N, 11.40. Found: C, 29.56; H, 2.79; N, 11.63.

## 4. Results and discussion

Reactions of  $\text{K}_2[\text{PtCl}_6]$ ,  $\text{K}_2[\text{PtCl}_4]$ ,  $\text{K}_2[\text{PdCl}_4]$ , and  $\text{PdCl}_2$  with **L** gave the complexes **1–4** (Scheme 1). The results of elemental analysis showed 1:2 and 1:1 metal/ligand stoichiometry for the complexes **1–3** and **4**, respectively. The analytical results were in good agreement with those required by the general formula  $\text{PtCl}_4\text{L}_2$  (**1**),  $\text{PtCl}_2\text{L}_2$  (**2**),  $\text{PdCl}_2\text{L}_2$  (**3**), and  $\text{Pd}_2\text{Cl}_4\text{L}_2$  (**4**). Crystals of these complexes could not be grown; therefore X-ray crystal determination was not possible. The compounds were characterized on the basis of the following studies.




Fig. 1. (Color online.) Optimized structure of **L** at the BP86/TZVP level of theory [20].




Fig. 2. (Color online.) The most stable *cis* and *trans* isomers of the optimized structures of complexes 1–4 at the BP86/TZVP level of theory.

#### 4.1. Structural characterization

Assignment of IR and NMR peaks (Tables 1 and 2) was performed according to the optimized structure of the ligand [20]; for the numbering of atoms see Fig. 1 (to see the spectra refer to Supplementary material, Figs. A.1–A.19).

Table 1 shows the most important vibrations in the ligand and the corresponding complexes. The comparative analysis of IR spectra of the complexes and of the free ligand revealed that the absorption bands characteristic of the stretching vibrations of  $-C=N-$  from the pyridine ring shifted towards the higher frequencies in the complexes. This indicates that the nitrogen atom from the pyridine ring participates in the coordination to the metal ion. The other characteristic bands of the pyridine ring of the free ligand are also shifted to the higher frequencies upon complexation. While the bands related to the stretching vibrations of the carbonyl groups remained almost unchanged in the all complexes, the stretching vibrations of NH groups have shifted to the lower frequencies. These changes may indicate a greater sensitivity of NH bonds to the coordination. The spectra of complexes 1–3 display a band in the low-energy region at  $390\text{--}300\text{ cm}^{-1}$  due to the M–Cl stretches, indicating that these complexes have a *trans* configuration [33]. The IR spectrum of 4,  $\text{Pd}_2\text{Cl}_2(\mu\text{-Cl})_2\text{L}_2$ , displays three  $\nu\text{Pd-Cl}$  bands attributable to the terminal and bridging Pd–Cl stretches as usually observed for these complexes [34–36].

The chemical shifts of NMR spectra for the ligand and the corresponding complexes are shown in Table 2.

In the  $^1\text{H}$  NMR spectra of the complexes, protons signals of the pyridine ring are shifted toward the lower frequencies compared to the spectrum of the ligand. There are noticeable differences between the protons chemical shifts of the ligand and those of the corresponding complexes. These show that in these complexes the most probable bonding of the ligand with the metal ion is realized through the nitrogen atom of the pyridine ring. Proton signal of N2–H3 group from the hydantoin ring

slightly shifted upon complexation, while the peak related to the more acidic NH group (N3–H4) had just appeared in the complex spectrum. These facts indicate that these atoms are not involved in the coordination. The impressive changes of the chemical shifts related to the carbon atoms of the pyridine ring also confirmed the participation of this ring in the binding with the metal ion. Signals of two C=O groups from the hydantoin ring in all complexes slightly changed. C8–O2 show greater shift toward higher frequencies than C6–O1, which can be because these groups are nearer to the coordination site. These findings are an indication that the hydantoin ring does not participate in the coordination.

Interestingly, we observed an isomerization of complex 3 to its *cis* derivative (Figs. A.12 and A.13). Thus when we recorded the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of a solution of *trans*-3 in DMSO at room temperature, we observed duplicated signals. These chemical shifts indicate that the coordination remained  $\text{PdCl}_2\text{N}_2$ , and a plausible explanation is a reversible *trans*-to-*cis* isomerization. These newly emerged NMR peaks were assigned to a *cis*-configuration. It is noteworthy that this phenomenon has not been observed for other complexes and is consistent with the results of our theoretical studies indicating a small energy difference between the *cis* and *trans* isomers in solution for this compound (please see theoretical studies).

#### 4.2. Theoretical studies

##### 4.2.1. Geometry optimization

The optimized geometry of L is shown in Fig. 1 and representative selected calculated bond parameters are listed in Table A.1. The distorted octahedral and square planar coordination configurations were observed for complexes 1 and 2–4, respectively. For each complex, there are two possible isomers, i.e. *cis* and *trans*. We can also consider four and six conformers for *trans* and *cis* isomers, respectively. Among all optimized isomers and related conformers (Figs. A.21–A.24), only the most stable *cis* and *trans* structures are shown in Fig. 2. Calculated total




Fig. 3. (Color online.) Correlations between theoretical and corresponding experimental values of  $^1\text{H}$  (a) and  $^{13}\text{C}$  (b) chemical shifts ( $\delta$ , ppm) for L and complexes 1–4.

energies for **1**, **2**, **3**, and **4** indicate that the *trans* isomers are by 18.8, 22.9, 23.4, and 50.9 kJ/mol more stable than the *cis* ones, respectively. The representative selected calculated bond parameters for most stable structures of **1–4** (*trans* isomers in Fig. 2) are listed in Tables A.2–A.5. In the case of **4**, there are varieties of bending angles between the coordination planes of two Pd atoms in all ten optimized structures. A theoretical and structural analysis of the binuclear complexes with unsubstituted bridges showed that a driving force for the bending of the molecules is the attractive metal...metal interaction that results from donor–acceptor interactions between the  $d_{z^2}$  and  $p_z$  orbitals of two metal atoms and is modulated by the nature of (a) the metal atom, (b) the terminal ligands, and (c) the bridging atoms [37]. Complexes with two good  $\sigma$ -donor (and preferably good  $\pi$ -acid) terminal ligands

(e.g., bipy, CO,  $PR_3$ , cod, or other diolefins) per metal atom favor bent structures, provided that no important steric hindrance occurs [37].

Since 50/50 (v/v) ethanol/water and acetonitrile/water solutions were used for obtaining complexes **1–3** and **4**, respectively, the CPCM with the dielectric constant of ethanol or water for **1–3** and acetonitrile or water for **4** was used for further calculations. In order to compare the stability of the structures, an averaged value of the electronic energy of the complexes in ethanol/water and acetonitrile/water solutions was calculated. The resulting data suggest that the *trans* isomer in solution, similar to the gas phase, is the more stable isomer in these complexes. The difference between the stabilities of the most stable *trans* and *cis* isomers in solution are 19.2, 15, 12.2 and 45.1 kJ/mol for **1**, **2**, **3**, and **4**, respectively.




Fig. 4. (Color online.) Antibacterial screening (a: inhibition zones (mm) and b: MIC values ( $\mu\text{g}\cdot\text{cm}^{-3}$ )) of the ligand and metal complexes; each datum represents the means  $\pm$  SE of 4–5 samples.

#### 4.2.2. $^1\text{H}$ and $^{13}\text{C}$ NMR calculations

For considering the correlation of  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of **L** and the corresponding complexes with calculated data obtained from their optimized structures, the quantum chemical calculations of shielding constants were performed. The absolute isotropic magnetic shielding constants ( $\sigma_i$ ) were used to obtain the chemical shifts (see Eq. (1)) by referring to the standard compound tetramethylsilane (TMS) for both the H and C atoms. The reference molecule TMS was also optimized and its isotropic NMR shielding constants were calculated using the same level of theory as for the studied structures.

$$\delta_i = \sigma_{\text{TMS}} - \sigma_i \quad (1)$$

As shown in Table 2 and in Fig. 3, the experimental  $^1\text{H}$  and  $^{13}\text{C}$  chemical shifts of all remarkable protons, except the acidic protons (of two  $-\text{NH}$  groups), and carbons for all compounds are in good agreement with the calculated values. Calculated values of acidic protons (H3 and H4 in **L**, Fig. 1) are unacceptable apart from the experimental values, showing obviously that the continuum model has not correctly described the chemical shifts associated with these protons and fails in reproducing the experimental findings for them [38–40]. However, as can be seen in Fig. 3, the high linear correlation coefficients ( $R^2$ ) established the robustness of the assignments. Thus it seems that the optimized and selected gas phase structures are close to those of these compounds in solution.

#### 4.3. Antibacterial activities

The antibacterial screening of the ligand and the metal complexes are shown in Fig. 4 (Table A.7). The inhibition was recorded by measuring the diameter of the inhibition zone for bacteria after 24 h. The activity of all these compounds was further confirmed by determining the minimum inhibitory concentration (MIC) values by the tube dilution method in which the effectiveness was observed at lower concentrations. For comparison, inhibition zones and MIC values of chloramphenicol standard were also indicated.

According to data, both the ligand and complexes individually exhibited varying degrees of inhibitory effects on the growth of the tested bacterial species. The antibacterial results evidently showed that the activity of the ligand became more pronounced when coordinated to the metal. The increased activity of the metal chelates can be explained on the basis of Tweedy's chelation theory [41], according to which the polarities of the ligand and the central metal atom are reduced through charge equilibration over the whole chelate ring. This increases the lipophilic character of the metal chelate and favors its permeation through the lipid layer of the bacterial membranes [42]. As can be seen in Fig. 4, a moderate to strong inhibition was detected towards bacteria strains with MIC values of 32–6  $\mu\text{g}\cdot\text{cm}^{-3}$ . In this regard, the highest antibacterial effect of **L** was against *S. aureus* (12  $\mu\text{g}\cdot\text{cm}^{-3}$ ), **1** and **2** against *E. coli* (10 and 16  $\mu\text{g}\cdot\text{cm}^{-3}$ ), and **3** and **4** against *S. saprophyticus* (18 and 12  $\mu\text{g}\cdot\text{cm}^{-3}$ ).

As a result, both in terms of inhibitory potency and MIC values, standard antibiotic chloramphenicol has stronger activity than the chemicals against these bacterial strains. Nevertheless, it is noteworthy that the inhibitory zone of **L** (against *S. aureus*) and **4** (against *S. saprophyticus*, *S. marcescens*, and *B. cereus*) is noticeable and comparable to that of chloramphenicol.

## 5. Conclusions

In this report, the synthesis of N:–M complexes of platinum (**1** and **2**) and palladium (**3** and **4**) with monodentate 5-methyl-5-(3-pyridyl)hydantoin, **L**, have been presented. The experimental data and comprehensive theoretical calculations invoking geometry optimization of different isomers showed that in these complexes the nitrogen atom of the pyridine ring is involved in metal bonding forming mononuclear octahedral (**1**) and square planar (**2** and **3**), and binuclear square planar (**4**) complexes with *trans* configuration. An interesting aspect of complex **3** is the inversion of configuration, confirmed by the observation of duplicated  $^1\text{H}$  and  $^{13}\text{C}$  NMR peaks. The excellent agreement was observed between the theoretical and experimental chemical shifts of the compounds. The synthesized compounds were screened for their antibacterial activity against six bacterial strains. Based on the obtained results, complexes showed higher activities as compared to the parent ligand and, in general, the most active was binuclear palladium(II) complex.

## Acknowledgments

We are grateful to Bu-Ali-Sina University for financial support.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.crci.2014.04.013>.

## References

- [1] C.A. Lopez, G.G. Trigo, Adv. Heterocycl. Chem. 38 (1985) 177–228.
- [2] A. Camerman, N. Camerman, Acta Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem., 27 (1971) 2205–2211.
- [3] D. Kushev, G. Gorneva, V. Enchev, E. Naydenova, J. Popova, S. Taxirov, L. Maneva, K. Grancharov, N. Spassovska, J. Inorg. Biochem. 89 (2002) 203–211.
- [4] S.J. Sabounchei, P. Shahriary, Y. Gholiee, S. Salehzadeh, H.R. Khavasi, A. Chehregani, Inorg. Chim. Acta 409 (2014) 265–275.
- [5] N.T. Abdel Ghani, A.M. Mansour, Inorg. Chim. Acta 373 (2011) 249–258.
- [6] S. Rani, S. Kumar, S. Chandra, Spectrochim. Acta, Part A 118 (2014) 244–250.
- [7] H.G. Aslan, S. Özcan, N. Karacan, Inorg. Chem. Commun 14 (2011) 1550–1553.
- [8] K. Sharma, R. Singh, N. Fahmi, Spectrochim. Acta, Part A 78 (2011) 80–87.
- [9] G.P. Radić, V.V. Glodović, Z.R. Ratković, S.B. Novaković, S. Garcia-Granda, L. Rocces, L. Menéndez-Taboada, I.D. Radojević, O.D. Stefanović, L.R. Čomić, S.R. Trifunović, J. Mol. Struct. 1029 (2012) 180–186.
- [10] M. Galanski, Recent Pat. Anti-Cancer Drug Discovery 1 (2006) 285–295.
- [11] M. Galanski, M.J. Jakupec, B.K. Keppler, Curr. Med. Chem. 12 (2005) 2075–2094.
- [12] R.K. Ameta, M. Singh, R.K. Kale, New J. Chem. 37 (2013) 1501–1508.



- [13] N.T. Abdel Ghani, A.M. Mansour, *Eur. J. Med. Chem.* 47 (2012) 399–411.
- [14] M. Juribašić, K. Molčanov, B. Kojić-Prodić, L. Bellotto, M. Kralj, F. Zani, L. Tušek-Božić, *J. Inorg. Biochem.* 105 (2011) 867–879.
- [15] B. Geeta, K. Shrivankumar, P.M. Reddy, E. Ravikrishna, M. Sarangapani, K.K. Reddy, V. Ravinder, *Spectrochim. Acta, Part A* 77 (2010) 911–915.
- [16] N.M. Aghatabay, M. Somer, M. Senel, B. Dulger, F. Gucin, *Eur. J. Med. Chem.* 42 (2007) 1069–1075.
- [17] A. Garoufis, S. Hadjidakou, N. Hadjiliadis, *Coord. Chem. Rev.* 253 (2009) 1384–1397.
- [18] S.J. Sabounchei, P. Shahriary, S. Salehzadeh, Y. Gholiee, H.R. Khavasi, *J. Mol. Struct.* 1051 (2013) 15–22.
- [19] S.J. Sabounchei, P. Shahriary, *Curr. Top. Med. Chem.* 13 (2013) 3026–3039.
- [20] S.J. Sabounchei, P. Shahriary, S. Salehzadeh, Y. Gholiee, D. Nematollahi, A. Chehregani, A. Amani, *New J. Chem.* 38 (2014) 1199–1210.
- [21] A.D. Becke, *Phys. Rev. A* 38 (1988) 3098–3100.
- [22] J.P. Perdew, *Phys. Rev. B* 33 (1986) 8822–8824.
- [23] F. Weigend, R. Ahlrichs, *Phys. Chem. Chem. Phys.* 7 (2005) 3297–3305.
- [24] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, J.A.J. Montgomery, T. Vreven, K.N. Kudin, J.C. Burant, J.M. Millam, S.S. Iyengar, J. Tomasi, V. Barone, B. Mennucci, M. Cossi, G. Scalmani, N. Rega, G.A. Petersson, H. Nakatsuji, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, M. Klene, X. Li, J.E. Knox, H.P. Hratchian, J.B. Cross, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, P.Y. Ayala, K. Morokuma, G.A. Voth, P. Salvador, J.J. Dannenberg, V.G. Zakrzewski, S. Dapprich, A.D. Daniels, M.C. Strain, O. Farkas, D.K. Malick, A.D. Rabuck, K. Raghavachari, J.B. Foresman, J.V. Ortiz, Q. Cui, A.G. Baboul, S. Clifford, J. Cioslowski, B.B. Stefanov, G. Liu, A. Liashenko, P. Piskorz, I. Komaromi, R.L. Martin, D.J. Fox, T. Keith, M.A. Al-Laham, C.Y. Peng, A. Nanayakkara, M. Challacombe, P.M.W. Gill, B. Johnson, W. Chen, M.W. Wong, C. Gonzalez, J.A. Pople, Gaussian software, Gaussian, Inc., Pittsburgh, PA, 2003.
- [25] V. Barone, M. Cossi, *J. Phys. Chem. A* 102 (1998) 1995–2001.
- [26] K. Wolinski, J.F. Hinton, P. Pulay, *JACS* 112 (1990) 8251–8260.
- [27] G. Magyrafalvi, P. Pulay, *J. Chem. Phys.* 119 (2003) 1350–1358.
- [28] A.A. Forbes, D.F. Sahm, A.S. Weissfeld, E.A. Trevino, *Method for testing antimicrobial effectiveness in diagnostic microbiology*, Bailey & Scott's, 1990.
- [29] A.D. Russel, J.R. Furr, *J. Appl. Bacteriol.* 43 (1977) 23–25.
- [30] M. Khan, A. Omoloso, *Fitoterapia* 74 (2003) 695–698.
- [31] N.C.f.C.L., Standards, performance standards for antimicrobial susceptibility testing, Ninth informational supplement, NCCLS document M100-S9, Wayne, PA, 2008.
- [32] C.C. Chu, P. Teague, *J. Org. Chem.* 23 (1958) 1578.
- [33] K. Nakamoto, *Infrared and Raman spectra of inorganic and coordination compounds: theory and applications in inorganic chemistry*, John Wiley, 1997.
- [34] R. Goodfellow, P. Goggin, L. Venanzi, *J. Chem. Soc. A* (1967) 1897–1900.
- [35] P.P. Phadnis, V.K. Jain, A. Knödler, W. Kaim, *Anorg. Allg. Chem.* 628 (2002) 1332–1338.
- [36] P.P. Phadnis, V.K. Jain, A. Klein, T. Schurr, W. Kaim, *New J. Chem.* 27 (2003) 1584–1591.
- [37] G. Aullón, G. Ujaque, A. Lledós, S. Alvarez, P. Alemany, *Inorg. Chem.* 37 (1998) 804–813.
- [38] V. Chiş, A. Pirmău, M. Vasilescu, R.A. Varga, O. Oniga, *J. Mol. Struct.: THEOCHEM* 851 (2008) 63–74.
- [39] N.T. Abdel Ghani, A.M. Mansour, *Spectrochim. Acta, Part A* 86 (2012) 605–613.
- [40] N.T. Abdel Ghani, A.M. Mansour, *Spectrochim. Acta, Part A* 81 (2011) 529–543.
- [41] B.G. Tweedy, *Phytopathology* 55 (1964) 910–914.
- [42] M. Tümer, D. Ekinci, F. Tümer, A. Bulut, *Spectrochim. Acta, Part A* 67 (2007) 916–929.